Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 6/20 | 0.42 |
| ▸ | PARP15 | Q460N3 | 5/20 | 0.42 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14817289 | 0.84 | PARP15 (0.46) | PARP10PARP15PARP2NR1H4DRD2 | |
| SCHEMBL16172295 | 0.83 | PARP10 (0.50) | PARP10PARP15PARP2FFAR4MAOB | |
| SCHEMBL12730862 | 0.83 | PARP15 (0.43) | PARP10PARP15PARP2NR1H4DRD2 | |
| SCHEMBL12787696 | 0.83 | MAPT (0.46) | PARP10PARP15PARP2DRD2DRD4 | |
| SCHEMBL12730859 | 0.82 | SIGMAR1 (0.45) | PARP10PARP15PARP2 | |
| SCHEMBL12730858 | 0.82 | LMNA (0.50) | PARP10PARP15PARP2 | |
| SCHEMBL12730774 | 0.82 | PARP15 (0.44) | PARP10PARP15PARP2NR1H4DRD2 | |
| SCHEMBL12730766 | 0.82 | PARP15 (0.44) | PARP10PARP15PARP2NR1H4DRD2 | |
| SCHEMBL8021673 | 0.82 | PARP10 (0.49) | PARP10PARP15PARP2FFAR4NR1H4 | |
| SCHEMBL8014459 | 0.82 | PARP10 (0.49) | PARP10PARP15PARP2FFAR4NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404316-B2 | Polymerizable liquid crystal compound and its polymer | JNC CORPORATION (JP) | 2013-03-26 | — | — | US | disclosed |
| US-8404316-B2 | Polymerizable liquid crystal compound and its polymer | JNC CORPORATION (JP) | 2013-03-26 | — | — | US | disclosed |
| US-20110086185-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND AND ITS POLYMER | CHISSO CORPORATION (JP) | 2011-04-14 | — | — | US | disclosed |
| US-20110086185-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND AND ITS POLYMER | CHISSO CORPORATION (JP) | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086185-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND AND ITS POLYMER | CCNT1, POF1B, CCND3 | PARP10 1455/4885PARP15 3114/4885PARP2 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.